Asha Pillai, MD

    Asha B. Pillai, MD

    Assistant Member, St. Jude Faculty

    Departments

    Bone Marrow Transplantation & Cellular Therapy

    Contact Information

    Asha Pillai, MD
    Bone Marrow Transplantation & Cellular Therapy
    MS 310, Room D5048E
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: asha.pillai@stjude.org

    Education

    BS – Microbiology and Immunology, Stanford University
    MD – Indiana University School of Medicine
    Pediatric Internship/Residency – Texas Children's Hospital, Baylor College of Medicine
    Pediatric Hem/Onc/BMT Fellowship – Packard Children's Hospital, Stanford University
    Internal Medicine Internship/Residency – Baylor College of Medicine
    Adult Hematology/BMT Fellowship – Stanford Hospital and Clinics, Stanford University


    Honors & Awards


    Research Interests

    Lab research foci:

    Translational and clinical research foci:

    Research lab


    Selected Publications

    *corresponding author

    Srinivasan A, Panetta JC, Cross S, Pillai A, Triplett B, Shook D, Dallas M, Hartford C, Kang G, Jacobsen J, Choi J, Leung W. Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia. Biol Blood Marrow Transplant 2014; PMID: 24769325; PMCID: pending.

    Martin J, Howard S, Pillai A, Vogel P, Naren AP, Davis S, Smith K, Buddington K, Buddington R. The weaned pig as a model for doxorubicin-induced mucositis. Chemotherapy 60:24-36, 2014. (DOI: 10.1159/000365725) http://www.karger.com/DOI/10.1159/000365725.

    van der Merwe M, Abdelsamed H, Seth A, Ong T, Vogel P, *Pillai A. Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ Treg proliferation and immune tolerance after murine non-myeloablative bone marrow transplantation. J Immunol Dec 1;191(11):5764-76, 2013. doi: 10.4049/jimmunol.1302191. Epub 2013 Nov 4. PMID: 24190658 PMCID: pending. Selected as feature article, December 1 edition.

    Rujkijyanont P, Morris C, Kang G, Gan K, Hartford C, Triplett B, Dallas M, Srinivasan A, Shook D, Pillai A, Leung W. Risk-adapted donor lymphocyte infusion based on chimerism and donor source. Blood Cancer J Aug 30;3:e137, 2013. doi: 10.1038/bcj.2013.39. PMID: 23995046.

    Shook D, Triplett B, Srinivasan A, Hartford C, Dallas M, Pillai A, Laver J, Leung W. Successful allogeneic hematopoieticcell engraftment following a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant 19(2):291-297, 2012. PMID: 23063628.

    Triplett B, Wang C, Yang J, Dallas M, Hartford C, Howard V, Pillai A, Shook D, Srinivasan A, Laver J, Leung W. Effects of conditioning regimens and T-cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant 18(8):1273-80, 2012. doi:10.1016/j.bbmt.2012.01.021. PMID: 22842333.

    Leung W, Pui C, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C,Triplett B, Dallas M, Pillai A, Shook D, Rubnitz J, Sandlund J, Jeha S, Inaba H, Ribeiro R, Handgretinger R, Laver J, Campana D. Detectable minimal residual diseasebefore hematopoietic cell transplantation is prognostic but does not preclude cure for children with very- high-risk leukemia. Blood 120(2):468-72, 2012. PMID: 22517895.

    Morales-Tirado V, Luszczek W,van der Merwe M,* Pillai A. Regulatory immunotherapy in bone marrow transplantation. (Invited review). TSW Hematology 11:2620-2634, 2011. doi:10.1100/2011/768948 (www.tswj.com/2011/768948).

    Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz J, Sandlund J, Ribeiro R, Srinivasan A, Hartford C, Triplett B, Dallas M, Pillai A, Handgretinger R, Laver J, Pui CH. High success of hematopoietic cell transplantation regardless of donor source in children with very-high-risk leukemia. Blood 118(2):223-30, 2011. PMID: 21613256.

    *Pillai A, Hartford C, Srinivasan A, Triplett B, Dallas M, Wang C, Yang J, Leung W. Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatric Transplantation 15(6):628-34, 2011. PMID: 21762328

    Pillai AB, Kohrt HJ, Lowsky R, Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. (Invited Review). Eur J Immunol 40(7):1862–9, 2010. PMID: 20583031

    *Pillai A, George T, Dutt S, Strober S. Host natural killer T cells induce an IL-4 dependent expansion of donor CD4 CD25 Foxp3 Tregs that protects against graft-versus-host disease. Blood 113(18):4458-67, 2009. PMID: 19221040

    Pillai A, Teo P, George T, Mukhopadhyay A, Dejhbahksh-Jones S, Strober S. Alloantigen recognition is required for CD8-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation. Bone Marrow Transplant 40 (5):487-97, 2007. PMID: 17603512

    Pillai A, George T, Dutt S, Teo P, Strober S. Natural killer T cells can prevent graft-versus host-disease and permit graft anti-tumor activity after bone marrow transplantation. J Immunol 178 (10): 6242-51, 2007. PMID: 17475852

    Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Krensky AM. Interleukin-3 is a growth factor for human follicular B-cell lymphoma. J Exp Med 175 (2):371-6, 1992. PMID: 1732410

    Last updated: November 2014